TITLE

GnRH antagonist versus agonist in normoresponders undergoing ICSI: a randomized clinical trial in Iran

AUTHOR(S)
Tebraninejad, Ensieh; Ghahghaei Nezamabadi, Akrain; Rashidi, Balool; Sohrabi, Maryam; Bagheri, Maiyam; Haghollahi, Fedyeh; Nekoo, Elham Azimi; Jafarabadi, Mina
PUB. DATE
July 2011
SOURCE
Iranian Journal of Reproductive Medicine;Summer2011, Vol. 9 Issue 3, p171
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: General concern is that the pregnancy rate is higher with GnRH-agonist as a protocol of pituitary suppression. GnRH-antagonist protocol provides a shorter period of administration and an easy flexible protocol. Objective: In this study, the outcomes of GnRH agonist and antagonist in ICSI cycles are compared in normo responder patients. Materials and Methods: In this randomized clinical trial, 300 normoresponders undergoing ICSI were randomly divided to GnRh agonist (n=150) and GnRh antagonist (n=150) groups. The main outcome measurements were chemical, clinical and ongoing pregnancy rates (PR). Results: The mean duration of stimulation were 9.6±1.6 and 8.2±1.6 days in agonist and antagonist groups respectively (p=0.001). The mean number of MII oocyte retrieved in agonist and antagonist groups were 73±4.0 and 6.9±4.3 respectively (p=0.03). There was no significant difference between two groups regarding mean number of gonadotrophin ampoules, follicles, occytes, total embryos and good quality embryos, OHSS incidence, and abortion rate. Chemical pregnancy rate was 35.3% in agonist and 39.3% in antagonist group. Clinical pregnancy rate was 35.3% in agonist and 34% in antagonist group. Ongoing pregnancy rate was 45 (31.3%) in agonist and 44 (29.3%) in antagonist group. There was no significant difference between two groups in pregnancy rates. Conclusion: In this study antagonist protocol was shown to be an easy, safe and friendly protocol in Iranian normoresponder patients, having similar outcomes with standard agonist protocol but shorter period of stimulation.
ACCESSION #
69849521

 

Related Articles

  • Effect of Combining Recombinant FSH with Recombinant LH on Oocyte and Embryo Quality in the GnRH Agonist Long and Antagonist Cycles. Kumbak, Banu; Kahraman, Semra // Journal of the Turkish-German Gynecological Association;Sep2008, Vol. 9 Issue 3, p120 

    Objective: Luteinizing hormone (LH) requirement in assisted reproductive treatment (ART) cycles is still controversial. The objective of this study was to investigate the impact of providing LH activity with recombinant LH (rLH) on the oocyte and embryo quality in both GnRH agonist long and...

  • Duration of Stimulation is Shorter with GnRH Antagonist for Poor Responders.  // Fertility Weekly;2/20/2012, p8 

    The article reports on the study conducted by D. Pu and colleagues which evaluates the efficacy of luteinizing hormone releasing hormone antagonist (GnRH-ant) versus GnRh agonist (GnRH-a) protocols for ovarian stimulation in poor responders of in vitro fertilization (IVF). The researchers...

  • Comparison between a GnRH antagonist and a GnRH agonist flare-up protocol in oocyte donors: a randomized clinical trial. D. Bodri; V. Vernaeve; J.J. Guillén; R. Vidal; F. Figueras; O. Coll // Human Reproduction;Sep2006, Vol. 21 Issue 9, p2246 

    BACKGROUND: Little information is available on the outcome of controlled ovarian hyperstimulation (COH) using GnRH antagonist in oocyte donation cycles especially in comparison with the short GnRH agonist protocol. This study was aimed at comparing the two stimulation protocols in oocyte...

  • Combination of a GnRH agonist with an antagonist prevents flare-up effects and protects primordial ovarian follicles in the rat ovary from cisplatin-induced toxicity: a controlled experimental animal study. Xiaoyan Li; Xiang Kang; Qingchun Deng; Jing Cai; Zehua Wang // Reproductive Biology & Endocrinology;2013, Vol. 11 Issue 1, p1 

    Background: With the continuous improvement of surgery and chemotherapeutic treatments, many tumour patients increasingly achieve long-term survival and can even be completely cured. However, platinum-containing drugs, which are widely used to treat a variety of types of cancer, cause menstrual...

  • GnRH Antagonist may be used for Poor Responders. Aletebi, Farma // Fertility Weekly;2/11/2008, p1 

    The article presents the study that compared the effect of Gonadotrophin-releasing hormone (GnRH) antagonist to that of GnRH agonist on poor ovarian responders conducted by Farma Aletebi. The study evaluated 23 patients who underwent ovarian stimulation with recombinant follicle-stimulating...

  • The role of GnRH antagonists in assisted reproduction. Barri, Pedro N.; Martinez, Francisca; Coroleu, Buenaventura; Tur, Rosa // Reproductive BioMedicine Online (Reproductive Healthcare Limited;Nov2002 Supplement 1, Vol. 5 Issue S1, p14 

    The different schemes of application of gonadotrophin-releasing hormone (GnRH) antagonists in ovarian stimulation protocols for assisted reproduction are reviewed. Starting from the initial schemes of single and/or multiple doses, the efficacy of GnRH antagonists in 'soft' protocols of ovarian...

  • Comparing GnRH agonist long protocol and gnrh antagonist protocol in outcome the first cycle of ART. Firouzabadi, Razieh; Ahmadi, Shahnaz; Oskouian, Homa; Davar, Robab // Archives of Gynecology & Obstetrics;Jan2010, Vol. 281 Issue 1, p81 

    This prospective study evaluated the efficacy of gonadotropin-releasing hormone (GnRH) antagonist protocol in comparison with the GnRH agonist protocol in the first cycle of assisted reproductive technique (ART). We randomized 235 patients undergoing ART for the first time. The first group was...

  • Benefits of luteinizing hormone activity in ovarian stimulation for IVF. Venetis, C. A; Kolibianakis, E. M.; Tarlatzi, T. B.; Tarlatzis, B. C. // Reproductive BioMedicine Online (Reproductive Healthcare Limited;2009 Supplement 2, Vol. 18 Issue S2, pS31 

    Knowledge of the physiology of folliculogenesis has led to a better understanding of the role of LH activity in this process. This role has been investigated in the setting of ovarian stimulation and several treatment modalities have been proposed. LH activity can be provided in the forms of:...

  • Ovarian stimulation in polycystic ovary syndrome patients: the role of body mass index. Orvieto, Raoul; Nahum, Ravit; Meltcer, Simion; Homburg, Roy; Rabinson, Jacob; Anteby, Eyal Y.; Ashkenazi, Jacob // Reproductive BioMedicine Online (Reproductive Healthcare Limited;Mar2009, Vol. 18 Issue 3, p333 

    In an attempt to examine whether body mass index (BMI) may influence IVF outcome in polycystic ovary syndrome (PCOS) patients undergoing ovarian stimulation with either gonadotrophin-releasing hormone (GnRH)-agonist (agonist group) or antagonist (antagonist group), 100 IVF cycles were studied:...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics